Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment | Zendy

Stacy E. Hatcher | Zendy; Emmanuelle Waubant | Zendy; Bardia Nourbakhsh | Zendy; Elizabeth CrabtreeHartman | Zendy; Jennifer Graves | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment

Author(s) -

Stacy E. Hatcher,

Emmanuelle Waubant,

Bardia Nourbakhsh,

Elizabeth CrabtreeHartman,

Jennifer Graves

Publication year - 2016

Publication title -

jama neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.298

H-Index - 231

eISSN - 2168-6157

pISSN - 2168-6149

DOI - 10.1001/jamaneurol.2016.0826

Subject(s) - fingolimod , multiple sclerosis , medicine , natalizumab , pediatrics , neurology , psychiatry

The appropriate sequencing of agents with strong immune system effects has become increasingly important. Transitions require careful balance between safety and protection against relapse. The cases presented herein highlight that rebound events after ceasing fingolimod treatment may happen even with short washout periods (4 weeks) and may perpetuate despite steroid treatment or the immediate use of fast-acting immune therapies, such as rituximab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research